Clinical Trial: NCT05400109
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | David Wald |
| Information Provided By: | Case Comprehensive Cancer Center |
| Last Update Posted: | 2026-05-05 |
Study Overview
Brief Summary
This study seeks to determine the safety and efficacy of the infusion of autologous CD19 CAR-T cells that are manufactured using an ultra-fast process.
Official Title
A Phase 1/1b Multicenter, Open Label Study to Evaluate the Safety of UF-KURE19 Cells in Patients With B Cell Non-Hodgkin Lymphomas
Conditions
Non Hodgkin Lymphoma
Intervention / Treatment
- Biological: UF-KURE19 CAR-T cells
- Drug: Fludarabine
- Drug: Cyclophosphamide
Other Study ID Numbers
- CASE2422
Start Date (Actual)
2023-04-26
Primary Completion Date (Estimated)
2026-10-01
Study Completion Date (Estimated)
2026-10-01
Enrollment (Actual)
21
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | David Wald |
| Information Provided By: | Case Comprehensive Cancer Center |
| Last Update Posted: | 2026-05-05 |
Study Overview
Brief Summary
This study seeks to determine the safety and efficacy of the infusion of autologous CD19 CAR-T cells that are manufactured using an ultra-fast process.
Official Title
A Phase 1/1b Multicenter, Open Label Study to Evaluate the Safety of UF-KURE19 Cells in Patients With B Cell Non-Hodgkin Lymphomas
Conditions
Non Hodgkin Lymphoma
Intervention / Treatment
- Biological: UF-KURE19 CAR-T cells
- Drug: Fludarabine
- Drug: Cyclophosphamide
Other Study ID Numbers
- CASE2422
Start Date (Actual)
2023-04-26
Primary Completion Date (Estimated)
2026-10-01
Study Completion Date (Estimated)
2026-10-01
Enrollment (Actual)
21
Study Type
Interventional
Phase
Phase 1